Network Insights Methodology Get Access

Novartis

ORG Health Care / Pharmaceuticals Momentum 11.2 NORMAL Primary: Spectral Shift

$95B revenue (Basel) cuts two oncology programs and pulls Pluvicto prostate cancer label expansion in EU while securing WHO prequalification for Coartem Baby malaria treatment. Portfolio management amid patent cliffs and generic competition pressure on radioligand therapies.

Recent program terminations in cancer-related blood clots; EU label expansion filing withdrawal for Pluvicto; WHO prequalification achieved for Coartem Baby malaria treatment; Lutathera facing upcoming generic competition
-0.30
PSI Score
11.2
Momentum
1%
Confidence
8
Connections
Connected Entities
Merck Pfizer United States European Union Anthropic China DOD CEO AstraZeneca Airbus Barclays Ohio Houston Massachusetts WHO
Watch This Entity
PSI Intelligence
30-Day Trend
2026-04-06 2026-04-30 8 0 Degree Mentions
Signal Decomposition
Attention Cascade
-0.385
Narrative Drift
0.000
Spectral Shift
545.978
Sentiment-Momentum Divergence
0.000
Source Concentration
0.901
Peer Comparison
N/A
Sector Rank
+0.00
Peer Z-Score
0%
Sector Percentile
Network Analysis
8 Degree Centrality
Centrality History
2026-04-06 2026-04-30 8 0 Degree Mentions
EntityWeight StatusFirst Seen
Merck 43 STRENGTHENED
Pfizer 43 STRENGTHENED
United States 5 STRENGTHENED
European Union 5 STABLE
Anthropic 4 NEW
China 3 STABLE
DOD 2 STABLE
CEO 2 STABLE
AstraZeneca 2 NEW
Airbus 2 NEW
Barclays 2 NEW
Ohio 1 NEW
Houston 1 NEW
Massachusetts 1 NEW
WHO 1 STABLE
Article Coverage (0)
DateLaneTitle

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-04-30 ← Intelligence Network